SECTION 01 / SELECTIVITY
Ipamorelin as a Selective Growth Hormone Secretagogue
The landmark characterization of ipamorelin was published in 1998 by Raun et al. in European Journal of Endocrinology. The study evaluated ipamorelin at 2.3–80 nmol/kg IV in rats and swine alongside equimolar doses of GHRP-2 and GHRP-6 [1][2].
In every model tested, ipamorelin produced dose-dependent, robust GH release. GHRP-2 and GHRP-6 did the same — but they also significantly elevated ACTH and cortisol. Ipamorelin did not. FSH, LH, prolactin, and TSH were unaffected by all three compounds [1][2].
The paper's conclusion was direct: ipamorelin is the first GH-releasing peptide to achieve selectivity comparable to GHRH, stimulating pituitary somatotrophs without activating the corticotroph axis. This distinguishes it from the earlier GHRP class and is the single most-cited result in the ipamorelin literature, with the 1998 paper accumulating more than 189 citations.
In vitro, the EC50 for GH release from primary rat pituitary cell cultures was approximately 1.3 nmol/L. Selectivity was maintained even at concentrations exceeding 200-fold the GH-releasing ED50 — a concentration range that, for GHRP-6, would produce significant ACTH and cortisol elevation [1].
SECTION 02 / MECHANISM
Ipamorelin Mechanism of Action
Ipamorelin acts as an agonist of GHS-R1a — the growth hormone secretagogue receptor type 1a, the active isoform of the ghrelin receptor. GHS-R1a is expressed on pituitary somatotrophs, hypothalamic arcuate neurons, and enteric nervous system cells [1][13].
Binding of ipamorelin to GHS-R1a activates intracellular calcium mobilization and cAMP signaling within somatotrophs, triggering the exocytosis of stored GH granules. This pathway is complementary to — not the same as — the GHRH receptor (GHRHR) pathway used by sermorelin and CJC-1295. GHRHR signals through adenylyl cyclase and protein kinase A; GHS-R1a signals through Gq/11 and phospholipase C. The two pathways converge on the same somatotroph, and co-activating them is the mechanistic basis for the ipamorelin and CJC-1295 stack concept [16][18][19].
Critically, the GH released by ipamorelin remains subject to endogenous somatostatin feedback — the inhibitory brake that governs physiologic GH pulsatility. This is a mechanistic distinction from exogenous recombinant GH, which bypasses somatostatin regulation entirely [17]. Ipamorelin's GH-releasing effect requires an intact, responsive pituitary gland.
Downstream, each GH pulse drives hepatic IGF-1 synthesis. The IGF-1 response is delayed relative to the GH pulse — measurable after multi-week dosing protocols in animal models — and mediates many of the downstream anabolic effects documented in the bone and tissue-repair literature [8][22].
SECTION 02a / GH RESPONSE
Ipamorelin-Induced GH Pulses in Preclinical Models
The peak GH response to ipamorelin occurs within 15–30 minutes of subcutaneous administration in published animal studies [1]. In female Sprague-Dawley rats dosed at 18, 90, and 450 µg/day via subcutaneous injection three times daily for 15 days (Johansen et al. 1999), longitudinal bone growth rate increased dose-dependently: from 42 µm/day at vehicle to 44, 50, and 52 µm/day at escalating doses, respectively (p<0.0001) — a finding attributable to the cumulative GH pulses driving IGF-1-mediated skeletal anabolism [3].
Chronic 21-day ipamorelin treatment in young female rats (Jiménez-Reina et al. 2002) increased the volume density of secretion granules in pituitary somatotroph cells. In vitro, somatotrophs from chronically treated animals showed enhanced GH response to a subsequent ipamorelin challenge at 10⁻⁸ M, with no evidence of tachyphylaxis (desensitization) under that protocol — relevant context for the receptor-desensitization question frequently raised in the research community [7].
GH release was also preserved in the presence of methylprednisolone. In female Wistar rats given methylprednisolone 5.0 mg/kg for 8 days, the acute GH response to ipamorelin (0.4–1.6 mg/kg/day IV × 4 doses/day) was not suppressed; IGF-1 levels and body weight recovered in the combination group compared to glucocorticoid alone [8].
SECTION 03 / SAFETY PROFILE
Ipamorelin Side Effects in Research Literature
In preclinical models, ipamorelin at research doses demonstrated a favorable tolerability profile in the studies reviewed. ACTH and cortisol were not significantly elevated — the primary safety differentiator versus GHRP-2 and GHRP-6 — and prolactin, FSH, LH, and TSH were not affected [1][2].
In the one Phase 2 randomized controlled human trial (NCT00672074, n=117), IV ipamorelin 0.03 mg/kg twice daily for up to 7 days was described as well tolerated, with no serious adverse reactions attributed to ipamorelin. Injection-site reactions and transient flushing have been noted in early-phase human study reports [11]. The trial enrolled bowel resection patients and was not designed to evaluate GH-axis safety endpoints.
One finding worth noting: Lall et al. (2001) showed that ipamorelin produced a small (~15%) increase in body weight and raised fat pad weights relative to body weight in both GH-deficient and GH-intact mice, alongside increased serum leptin and food intake. This GH-independent adiposity effect — also observed with GHRP-6 — suggests the compound may stimulate adiposity through pathways beyond the GH/IGF-1 axis [10]. Researchers studying body composition endpoints should account for this finding.
GAP IN EVIDENCE / HUMAN DATA
The question of whether ipamorelin is safer than exogenous recombinant GH is not settled in the published literature. The mechanistic difference — pulsatile secretion subject to somatostatin feedback versus continuous pharmacologic GH elevation — is well documented; the clinical consequence of that difference has not been evaluated in controlled human trials.
Reported Adverse Effects in Research Literature
In preclinical models, ipamorelin at research doses showed a favorable tolerability profile; injection-site reactions and transient flushing have been noted in early-phase human studies. Cortisol and prolactin were not significantly elevated at doses producing robust GH release in published protocols [1][11]. The one completed Phase 2 human trial reported no serious adverse reactions attributed to the compound.
SECTION 04 / IGF-1 AXIS
Ipamorelin and IGF-1 Elevation
IGF-1 is the primary downstream biomarker of GH-axis activation and the standard measure used in GH secretagogue research. Sustained ipamorelin dosing increases circulating IGF-1 as a consequence of elevated GH pulses — documented in the glucocorticoid model (Malmlöf et al. 1999) where combined ipamorelin + methylprednisolone treatment raised IGF-1 above glucocorticoid-alone levels and restored body weight [8][22].
The IGF-1 response is not immediate. GH elevation from a single injection peaks and resolves within hours; IGF-1 changes reflect the cumulative hepatic response to repeated GH pulses over days to weeks. In the Andersen et al. (2001) bone model (100 µg/kg SC × 3/day for 3 months), periosteal bone formation rate increased four-fold in the combined ipamorelin + glucocorticoid group compared to glucocorticoid alone — an effect mediated substantially through the GH-IGF-1 cascade [4].
Individual IGF-1 responsiveness to ipamorelin has not been characterized in human studies. Forum-sourced observational reports suggest variable IGF-1 responses; this is consistent with the recognized variability in GH-axis sensitivity across individuals and is not specifically ipamorelin data.
Ipamorelin and IGF-1 Response
Preclinical models show sustained ipamorelin dosing increases circulating IGF-1 as a downstream consequence of elevated GH pulses. In the Malmlöf et al. (1999) glucocorticoid model, ipamorelin prevented the glucocorticoid-associated decline in IGF-1 and restored body weight recovery [8][22]. Individual responsiveness varies; IGF-1 is not uniformly raised in all observational reports, consistent with the known interindividual variability of the GH/IGF-1 axis.
SECTION 05 / BONE RESEARCH
Ipamorelin and Bone Formation in Preclinical Studies
Bone research constitutes some of the most detailed published work on ipamorelin's downstream effects. Three papers are directly relevant.
Johansen et al. (1999) demonstrated dose-dependent longitudinal bone growth in female Sprague-Dawley rats: 18, 90, and 450 µg/day via subcutaneous three-times-daily injection for 15 days increased tibial growth plate rate from 42 µm/day (vehicle) to 44, 50, and 52 µm/day, respectively (p<0.0001), alongside dose-dependent body weight gain [3].
Svensson et al. (2000) studied ipamorelin and GHRP-6 at 0.5 mg/kg/day via subcutaneous osmotic minipump for 12 weeks in 13-week-old female Sprague-Dawley rats. Both compounds increased total tibial and vertebral bone mineral content by DXA compared to vehicle-treated controls. Bone dimensions increased; volumetric bone mineral density was unchanged, indicating growth occurred through expansion of bone geometry rather than densification [5].
Andersen et al. (2001) addressed the clinically relevant question of whether ipamorelin could counteract glucocorticoid-induced bone loss — the most common cause of secondary osteoporosis. In 8-month-old female Wistar rats receiving methylprednisolone 9 mg/kg/day, ipamorelin 100 µg/kg SC × 3/day for 3 months produced a four-fold increase in periosteal bone formation rate compared to glucocorticoid alone, and significantly improved maximum tetanic tension in muscle — a proxy for the integrated musculoskeletal anabolic response [4].
These findings establish a multi-study rodent case for ipamorelin's GH-mediated skeletal anabolic effect. Human bone data for ipamorelin does not exist in the published literature.
Ipamorelin and Bone Formation in Glucocorticoid Models
Andersen et al. (2001; PMID 11735244) showed ipamorelin prevented glucocorticoid-induced reductions in bone formation markers in an adult rat model, producing a four-fold increase in periosteal bone formation rate in the ipamorelin + methylprednisolone group versus glucocorticoid alone. Maximum tetanic tension was also significantly improved in the combination group [4].
SECTION 06 / GI MOTILITY
Ipamorelin in Postoperative Gastrointestinal Research
Ipamorelin's GHS-R1a agonism extends beyond the pituitary. GHS-R1a receptors are expressed in the enteric nervous system, where ghrelin-pathway activation drives prokinetic effects — accelerated gastric emptying, enhanced migrating motor complex, and stimulation of GI smooth muscle contractility through cholinergic and tachykininergic pathways [13].
Venkova et al. (2009) evaluated ipamorelin in a rat model of postoperative ileus induced by laparotomy and intestinal manipulation. At 0.1 or 1 mg/kg IV × 4 doses/day at 3-hour intervals, ipamorelin significantly increased cumulative fecal output, food intake, and body weight gain over 48 hours compared to vehicle. A single dose of 0.1–1 mg/kg also decreased time to first bowel movement versus control [6].
This GI motility research formed the basis for the one human clinical trial involving ipamorelin. A Phase 2 randomized, double-blind, placebo-controlled trial (NCT00672074, Bochicchio et al. 2014; n=117) administered ipamorelin 0.03 mg/kg IV twice daily for up to 7 days in bowel resection patients. Median time to first tolerated meal was 25.3 hours (ipamorelin) versus 32.6 hours (placebo); the difference did not reach statistical significance (p=0.15). The safety profile was described as well tolerated [11].
The GI motility indication represents the most clinically advanced chapter of the ipamorelin research record — the one domain where data from human patients exists, even if the trial did not meet its endpoint.
Ipamorelin and GI Motility
Multiple animal studies including Venkova et al. (2009) document ipamorelin's prokinetic effects on gastrointestinal contractility. The GI motility research — and the one Phase 2 human trial derived from it (NCT00672074) — represents the most clinically advanced chapter of the ipamorelin literature and the only body of work that includes human patient data [6][11][13].
Ipamorelin and Adipose Tissue in Research Models
Some rodent studies show GH secretagogues influence adiposity pathways — including GH-independent routes. Lall et al. (2001) showed ipamorelin increased fat pad weight and leptin in both GH-intact and GH-deficient mice at twice-daily subcutaneous injection for 2 weeks [10]. Direct belly-fat reduction by ipamorelin alone has not been demonstrated in controlled human trials; the GH-independent adiposity finding suggests ipamorelin's metabolic effects on adipose tissue are more complex than simple lipolysis.
Ipamorelin Selectivity: Cortisol and Prolactin Outcomes
Raun et al. (1998) showed ipamorelin did not significantly elevate ACTH, cortisol, or prolactin in rat and swine models at doses producing robust GH release — a key finding distinguishing it from GHRP-2 and GHRP-6, which elevated ACTH and cortisol at equimolar doses. FSH, LH, and TSH were also unaffected by all three compounds in the comparative study [1][2].
Ipamorelin as the First Selective GHS
The 1998 Raun et al. paper in European Journal of Endocrinology characterized ipamorelin as the first GHS that did not significantly elevate ACTH, cortisol, or prolactin, distinguishing it from earlier peptide secretagogues like GHRP-6 and GHRP-2. The characterization of ipamorelin as the "first selective growth hormone secretagogue" in the paper's title reflects this cortisol/prolactin-sparing profile at the in vivo and in vitro doses studied [1].
Pulsatile vs Continuous GH Elevation: Research Implications
Physiologic GH release is pulsatile — governed by alternating GHRH stimulation and somatostatin inhibition. Ipamorelin preserves pulsatility and requires intact pituitary function; the GH it releases is endogenous and subject to the usual feedback regulation [17]. Exogenous recombinant GH produces a continuous elevation that bypasses somatostatin feedback entirely. Researchers have theorized that this mechanistic difference may carry a different safety profile. Direct long-term controlled human comparison data between secretagogue-derived pulsatile GH and pharmacologic exogenous GH is absent from the current published literature.